Get startedLog in
    Picture of Corcept Therapeutics Incorporated logo

    CORT — Corcept Therapeutics Incorporated News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapHigh Flyer
    All News

    Brief: FDA Approves Relacorilant With NAB-Paclitaxel For Platinum-Resistant Epithelial Ovarian, Fallopian Tube,Primary Peritoneal Cancer

    Picture of Corcept Therapeutics Incorporated logoCorcept Therapeutics Incorporated
    25/03/2026 14:59
    March 25 (Reuters) - US FDA:

FDA APPROVES RELACORILANT WITH NAB-PACLITAXEL FOR PLATINUM-RESISTANT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER

Further company coverage: CORT.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Corcept Therapeutics Incorporated

    See all news